Spectranetics expanded indication
This article was originally published in The Gray Sheet
Executive Summary
Data showing the CVX-300 excimer laser catheter can be used at physicians' discretion for safe removal of atherosclerotic plaque and thrombus from coronary arteries following acute myocardial infarction will be presented Sept. 15 at TCT conference in Washington, D.C. The 151-patient CARMEL study supported a PMA supplement for the new indication, approved by FDA Aug. 13 (1"The Gray Sheet" July 21, 2003, p. 14)...
You may also be interested in...
Spectranetics Refocuses On CLI Indication After PELA Submission Setback
Spectranetics is considering whether to continue to pursue a claudication indication for its CVX-300 excimer laser in light of disappointing peripheral excimer laser angioplasty (PELA) trial results
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.